Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

A new protocol after heart attacks could slash risk of repeat events

NCT ID NCT07773272

Disease control Sponsor: Zuyderland Medisch Centrum Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time

Summary

This trial tests whether starting a comprehensive, guideline-based treatment plan immediately after a heart attack can reduce the chance of another heart attack, stroke, or death. The plan targets key risk factors like high cholesterol, high blood pressure, and diabetes using a combination of medications. About 1,200 adults who had a heart attack and underwent a stent procedure will be enrolled. Half will receive this rapid protocol, while the other half gets standard care, and outcomes are compared over two years.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Rapid ESC-guideline-based secondary prevention protocol including lipid-lowering, antihypertensive, SGLT-2 inhibitors, and GLP-1 agonists
What this could lead to
If effective, this approach could become a standard protocol to prevent recurrent heart attacks and strokes, improving survival and quality of life.
What could go wrong
The trial is testing a protocol, not a single drug, so results may vary. It's uncertain whether the rapid approach will outperform standard care in reducing events.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,215 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Mar 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consists of patients, hospitalised in Zuyderland, who underwent a percutaneous coronary intervention due to an acute coronary syndrome (unstable angina (UA), ST-elevation myocardial infarction (STEMI), or non ST-elevation myocardial infarction (non-STEMI)).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \> 18 years * Hospitalised with acute coronary syndrome * Underwent percutaneous coronary intervention Exclusion Criteria: * Acute coronary syndrome secondary to other diseases * Life expectancy \< 1 year based on the clinician's expertise

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute coronary syndrome diabetes mellitus hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) Cardiovascular risk management Diabete mellitus Hypercholerolemia Hypertension

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cardiology

    RECRUITING

    Heerlen, Limburg, 6419 PC, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.